Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,101 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,000)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05555901 | The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal Cancer | unknown | Phase 2 | 116 | Fudan UniversityOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT05783076 | SBRT Plus vNKT for Pancreatic Cancer | unknown | Phase 2 | 29 | Changhai HospitalOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT06017141 |
| Inhalational or Intravenous Anesthesia During Surgery for Patients With Colon Cancer, VIVA Study |
| unknown |
| Phase 2 |
| 80 |
| University of Kansas Medical CenterOTHER |
| 1 |
| Aug 30, 2023 |
| clinicaltrials |
| NCT06010888 | Fruquintinib With mFOLFOX6/FOLFIRI as First-Line Therapy for Conversion Surgery in mCRC | unknown | Phase 2 | 92 | Fudan UniversityOTHER | 1 | Aug 25, 2023 | clinicaltrials |
| NCT06008925 | Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer | unknown | Phase 1 / Phase 2 | 43 | CNBG-Virogin Biotech (Shanghai) Ltd.INDUSTRY | 1 | Aug 24, 2023 | clinicaltrials |
| NCT06010212 | Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma | unknown | Phase 1 / Phase 2 | 36 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Aug 24, 2023 | clinicaltrials |
| NCT05957016 | Neoadjuvant CIETAI With Concurrent Chemoradiotherapy in Local Advanced Rectal Cancer | unknown | Phase 2 | 90 | Third Military Medical UniversityOTHER | 1 | Aug 23, 2023 | clinicaltrials |
| NCT06003998 | Intraperitoneal Irinotecan With Concomitant FOLFOX and Bevacizumab(INTERACT-II) | unknown | Phase 2 | 85 | Catharina Ziekenhuis EindhovenOTHER | 1 | Aug 22, 2023 | clinicaltrials |
| NCT04984369 | The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment | unknown | Phase 2 | 50 | Shanghai Henlius BiotechINDUSTRY | 1 | Aug 21, 2023 | clinicaltrials |
| NCT05996484 | Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma | unknown | Phase 2 | 25 | Nanfang Hospital, Southern Medical UniversityOTHER | 0 | Aug 21, 2023 | clinicaltrials |
| NCT04659382 | Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer(SIRTCI) | unknown | Phase 2 | 52 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT04798612 | Effect of Low-dose Interferon-alfa2a on Peri-operative Immune Suppression(IPOS) | unknown | Phase 2 | 68 | Zealand University HospitalOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05997459 | A Single Arm, Phase II Exploratory Clinical Study of Pemitinib in Advanced Gastric Cancer With Previous Standard Therapy Failure the FGFR Variant | unknown | Phase 2 | 23 | Sun Yat-sen UniversityOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT04135690 | HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial | unknown | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT05023109 | GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC | unknown | Phase 2 | 45 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT05156788 | Tislelizumab(Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer | unknown | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT05235906 | A Phase II Clinical Study of Surufatinib Combined With Sintilimab in the Treatment of Advanced Gastric Cancer | unknown | Phase 2 | 61 | Sun Yat-sen UniversityOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05982834 | Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC | unknown | Phase 1 / Phase 2 | 43 | Fudan UniversityOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05127759 | The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation | unknown | Phase 2 | 25 | Shanghai Henlius BiotechINDUSTRY | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05982301 | Sintilimab Combined With Modified FLOT Regimen in the Treatment of Metastatic Gastric Cancer | unknown | Phase 2 | 87 | Fudan UniversityOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05974059 | Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer | unknown | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05971199 | Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma | unknown | Phase 2 | 27 | Zhejiang Cancer HospitalOTHER | 1 | Aug 2, 2023 | clinicaltrials |
| NCT04250948 | Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer | unknown | Phase 2 | 108 | Sun Yat-sen UniversityOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05842525 | Fruquintinib Plus FOLFIRI in RAS-mutated Metastatic Colorectal Cancer | unknown | Phase 2 | 42 | Hunan Cancer HospitalOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05911789 | Online Adaptive Radiation Therapy for Rectal Cancer | unknown | Phase 1 / Phase 2 | 15 | Peking Union Medical College HospitalOTHER | 0 | Aug 1, 2023 | clinicaltrials |
| NCT05970302 | XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC | unknown | Phase 2 | 52 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05970705 | Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC | unknown | Phase 2 | 101 | Fudan UniversityOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05871333 | Effect of Losartan on the Incidence and Severity of Chemotherapy-Induced Mucositis in Gastrointestinal Cancer Patients | unknown | Phase 2 | 80 | Ain Shams UniversityOTHER | 1 | Jul 19, 2023 | clinicaltrials |
| NCT04653480 | Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC | unknown | Phase 2 | 61 | Zhejiang UniversityOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT05948449 | To Evaluate the Efficacy and Safety of Cadonilimab With SOX as Neoadjuvant Therapy for Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. | unknown | Phase 2 | 37 | Sichuan UniversityOTHER | 0 | Jul 17, 2023 | clinicaltrials |
| NCT05281003 | Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)(HYPERION) | unknown | Phase 2 | 128 | Fudan UniversityOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT05576909 | Donafenib Combined With Hepatic Artery Chemoembolization for Perioperative Treatment of Liver Transplantation | unknown | Phase 2 | 20 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT04267549 | Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer | unknown | Phase 2 | 47 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT05928897 | Efficacy and Safety of Disitamab Vedotin Combined With Sintilimab | unknown | Phase 2 | 30 | Xiangya Hospital of Central South UniversityOTHER | 0 | Jul 5, 2023 | clinicaltrials |
| NCT05925413 | Cadonilimab Plus TACE in Patients With Intermediate-stage Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 41 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT04797884 | Electromagnetic Fields Versus Placebo For Child-Pugh A and B Patients With Advanced Hepatocellular Carcinoma(ARTEMIS) | unknown | Phase 2 / Phase 3 | 166 | THERABIONIC INC.OTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT05823987 | Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05)(OPTIONS-05) | unknown | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT05897268 | Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10)(CASTLE-10) | unknown | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT05919095 | A Clinical Study of a Preoperative Translational Therapy for Unresectable Gallbladder Cancer | unknown | Phase 2 | 37 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT02560298 | Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer(InterAACT) | unknown | Phase 2 | 91 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 22, 2023 | clinicaltrials |
| NCT04803851 | Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 29 | Peking Union Medical College HospitalOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05751265 | Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer | unknown | Phase 2 | 39 | Fujian Cancer HospitalOTHER_GOV | 0 | Jun 22, 2023 | clinicaltrials |
| NCT05911425 | Combined Treatment of Treated Bile Duct Cancer(CHOL) | unknown | Phase 2 | 30 | Zhejiang Cancer HospitalOTHER | 0 | Jun 22, 2023 | clinicaltrials |
| NCT05913570 | Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III MSI-H/dMMR Colorectal Cancer(MSI-H/dMMR) | unknown | Phase 2 | 22 | LiuYingOTHER_GOV | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05913661 | Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05908916 | Atezolizumab and Bevacizumab With Combined Radiotherapy for Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 51 | Yonsei UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05903456 | Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular Carcinoma | unknown | Phase 2 | 20 | Zhejiang Cancer HospitalOTHER | 0 | Jun 15, 2023 | clinicaltrials |
| NCT03073694 | Comparing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis | unknown | Phase 2 | 100 | University of Kansas Medical CenterOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT05896787 | Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC) | unknown | Phase 2 | 45 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT05160896 | SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer | unknown | Phase 2 | 90 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 8, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Aug 30, 2023source: clinicaltrials